reference/14844227

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14844227

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	20
issn	1352-0504 1365-2893
issueIdentifier	S1
pageRange	12-20
publicationName	Journal of Viral Hepatitis
startingPage	12
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d8bf1b8a20fd2206046febe5b38ecb1a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1962578c9146c78546870c1c183b0aa8 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9be8eadefa425a18fe892692d83bdb89
bibliographicCitation	Li SY, Li H, Xiong YL, Liu F, Peng ML, Zhang DZ, Ren H, Hu P. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat. 2017 Nov;24 Suppl 1():12–20. doi: 10.1111/jvh.12755. PMID: 29082649.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8481-0841 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b86a4b7b432a8c78048ef7af01dd8f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40c606c926a39bea91ab93c555020817 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a72e73b77d16253643db011fd121ffa0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff0389d7f81fa591e962da9a1866335d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_312022353af250a6d6c6ea0fa8a9000b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83003a06ecddcb00b42750df93639170 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_689d0cebb0c425c79017b88bc4326727
date	2017-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/29082649 https://doi.org/10.1111/jvh.12755
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8796 https://portal.issn.org/resource/ISSN/1365-2893 https://portal.issn.org/resource/ISSN/1352-0504
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg‐positive chronic hepatitis B: A five‐year observational cohort study
discusses	http://id.nlm.nih.gov/mesh/M0023752 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0370336 http://id.nlm.nih.gov/mesh/M0025711 http://id.nlm.nih.gov/mesh/M0010216
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006513Q000097 http://id.nlm.nih.gov/mesh/D006515Q000276 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D019694Q000097 http://id.nlm.nih.gov/mesh/D016898Q000627 http://id.nlm.nih.gov/mesh/D019694Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D015331 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D016898Q000008 http://id.nlm.nih.gov/mesh/D006513Q000276 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006147Q000009 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006147Q000627 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D064420Q000453 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D015994 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D015415 http://id.nlm.nih.gov/mesh/D064420Q000209 http://id.nlm.nih.gov/mesh/D016898Q000009 http://id.nlm.nih.gov/mesh/D019694Q000276 http://id.nlm.nih.gov/mesh/D019694Q000175
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_850d3dd3f0465864f03b25f855d284d1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10398 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398508 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7989 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7739 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998

Total number of triples: 68.